Guerbet Logo

Guerbet

Offers medical imaging solutions, from contrast agents to AI, for healthcare professionals.

GBT | PA

Overview

Corporate Details

ISIN(s):
FR0000032526 (+3 more)
LEI:
969500WV1U1WQ059L135
Country:
France
Address:
15 RUE DES VANESSES, 93420 VILLEPINTE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Guerbet is a global leader in medical imaging, specializing in diagnostic and interventional imaging solutions for healthcare professionals. Since its establishment in 1926, the company has developed and commercialized a comprehensive portfolio that includes contrast agents, medical devices, delivery systems, and digital and AI-powered solutions. Guerbet's products are utilized to improve the diagnosis and treatment of major disease areas such as cancer, as well as cardiovascular, inflammatory, and neurodegenerative diseases. The company focuses on providing innovative and safe solutions to enhance patient care and support radiology professionals worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-02 17:45
Business and Financial Review
GUERBET : Ajustement des objectifs financiers 2025.
French 157.0 KB
2025-12-02 17:45
Earnings Release
GUERBET : Adjustment of 2025 financial targets.
English 150.5 KB
2025-11-24 17:44
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 153.1 KB
2025-11-19 13:47
Report Publication Announcement
GUERBET : Calendrier financier de l’exercice 2026
French 198.7 KB
2025-11-19 13:47
Report Publication Announcement
GUERBET : Financial agenda for 2026
English 172.2 KB
2025-10-23 17:45
Earnings Release
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3…
French 294.9 KB
2025-10-23 17:45
Earnings Release
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmat…
English 305.6 KB
2025-10-14 17:30
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 158.6 KB
2025-09-24 17:45
Earnings Release
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on…
English 524.6 KB
2025-09-24 17:45
Earnings Release
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387…
French 496.3 KB
2025-09-22 17:45
Board/Management Information
Guerbet : Evolution de la Direction Générale
French 134.4 KB
2025-09-22 17:45
Board/Management Information
Guerbet : Change in General Management
English 113.8 KB
2025-09-18 17:45
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 159.1 KB
2025-09-15 17:50
Earnings Release
Guerbet : Ajustement des objectifs financiers annuels 2025
French 209.3 KB
2025-09-15 17:50
Earnings Release
Guerbet : Adjustment of 2025 full-year financial targets
English 186.1 KB

Automate Your Workflow. Get a real-time feed of all Guerbet filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Guerbet

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Guerbet via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 N/A Other Buy 142 4,989.31 EUR
2024-08-15 N/A Other Buy 195 6,678.75 EUR
2024-08-12 N/A Other Buy 1,000 34,350.00 EUR
2024-04-18 N/A Other Sell 550 17,699.00 EUR
2023-11-30 N/A Other Sell 700 12,684.00 EUR
2023-11-03 N/A Other Buy 1 17.92 EUR
2023-10-30 N/A Other Buy 1,000 17,000.00 EUR
2023-10-25 N/A Other Buy 1,000 16,800.00 EUR
2023-10-24 N/A Other Buy 1,000 16,460.90 EUR
2023-05-04 N/A Other Buy 300 4,938.00 EUR

Peer Companies

AVACTA GROUP PLC Logo
Developing targeted cancer therapies with a platform that delivers drugs directly to tumors.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Delivers clinical lab services & develops diagnostics, CAR-T therapies, and exosome technology.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axogen, Inc. Logo
Develops surgical solutions, including nerve allografts, for peripheral nerve repair and regeneration.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU
Azitra, Inc. Logo
Developing engineered proteins and live biotherapeutics for rare skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Develops T cell immunotherapies for autoimmune and chronic infectious diseases.
United States of America
BRNS

Talk to a Data Expert

Have a question? We'll get back to you promptly.